论文部分内容阅读
目的:探讨非对比剂增强磁共振血管成像(NCE-MRA)在评估肝脏门静脉解剖中的临床价值,并与MSCT门静脉成像(MSCTP)进行对照。方法:选择30例受试者分别行SLEEK序列NCE-MRA和MSCTA门静脉成像检查,其中肝硬化10例,肝癌10例,健康体检者10例。由两位医师分别对所有患者的NCE-MRA和MSCTP门静脉成像质量进行评分(4级评分法)并进行统计学分析。结果:NCE-MRA组和MSCTP组中,门静脉成像质量评分在2分以上者分别占93.3%(28/30)和96.7%(29/30)。两种方法均能显示所有受试者的3级及3级以下的肝内门静脉,符合率为100%(30/30)。2例(6.7%)健康志愿者的门静脉第6级分支在NCE-MRA上未显示,而在CTP上可以显示;3例(10%)肝硬化门静脉高压患者的门静脉第5级分支在CTP上未显示,而在NCE-MRA上可以显示;2例(6.7%)肝肿瘤患者门静脉的部分第4级分支在CTP上未显示,而在NCE-MRA上可以显示。两种方法的门静脉图像质量评分的差异无统计学意义(P<0.05),两位诊断医师对NCE-MRA门静脉成像质量评分的一致性较高,Kappa值为0.95。结论:SLEEK序列NCE-MRA是一种无需使用对比剂的非侵入性血管成像方法,能有效地对肝脏门静脉进行评估。
Objective: To investigate the clinical value of non-contrast enhanced magnetic resonance angiography (NCE-MRA) in the assessment of hepatic portal vein dissection and to compare it with MSCT portal vein imaging (MSCTP). Methods: 30 subjects were selected SLEEK sequence NCE-MRA and MSCTA portal vein imaging examination, including 10 cases of liver cirrhosis, liver cancer in 10 cases, 10 healthy subjects. Two physicians scored portal vein imaging of NCE-MRA and MSCTP in all patients (grade 4) and performed statistical analysis. Results: In the NCE-MRA group and the MSCTP group, the portal vein imaging quality score of 2 was 93.3% (28/30) and 96.7% (29/30), respectively. Both methods showed that the intrahepatic portal vein of grade 3 and lower in all subjects showed 100% (30/30) coincidence. In 2 healthy volunteers (6%), portal vein grade 6 branches were not shown on NCE-MRA but on CTP; portal vein grade 5 branches were found on CTP in 3 (10%) cirrhotic patients with portal hypertension Not shown, but can be shown on NCE-MRA; part of the grade 4 branch of the portal vein in 2 patients (6.7%) had no evidence of CTP and were shown on NCE-MRA. There was no significant difference in portal vein image quality scores between the two methods (P <0.05). The two diagnostic physicians had a higher consistency of NCE-MRA portal vein imaging quality score with a Kappa value of 0.95. Conclusion: SLEEK sequence NCE-MRA is a noninvasive vascular imaging method without contrast agent, which can effectively evaluate the hepatic portal vein.